AU2016307050A1 - Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation - Google Patents
Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation Download PDFInfo
- Publication number
- AU2016307050A1 AU2016307050A1 AU2016307050A AU2016307050A AU2016307050A1 AU 2016307050 A1 AU2016307050 A1 AU 2016307050A1 AU 2016307050 A AU2016307050 A AU 2016307050A AU 2016307050 A AU2016307050 A AU 2016307050A AU 2016307050 A1 AU2016307050 A1 AU 2016307050A1
- Authority
- AU
- Australia
- Prior art keywords
- leu
- ala
- val
- gly
- gln
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001126—CD38 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/10—Cellular immunotherapy characterised by the cell type used
- A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
- A61K40/31—Chimeric antigen receptors [CAR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/421—Immunoglobulin superfamily
- A61K40/4211—CD19 or B4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K40/00—Cellular immunotherapy
- A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
- A61K40/41—Vertebrate antigens
- A61K40/42—Cancer antigens
- A61K40/4202—Receptors, cell surface antigens or cell surface determinants
- A61K40/4222—CD38 not IgG
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0634—Cells from the blood or the immune system
- C12N5/0636—T lymphocytes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/515—Animal cells
- A61K2039/5158—Antigen-pulsed cells, e.g. T-cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55522—Cytokines; Lymphokines; Interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
- A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
- A61K2239/48—Blood cells, e.g. leukemia or lymphoma
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
- C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2510/00—Genetically modified cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biomedical Technology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Pharmacology & Pharmacy (AREA)
- Cell Biology (AREA)
- Biotechnology (AREA)
- Wood Science & Technology (AREA)
- Oncology (AREA)
- Mycology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Engineering & Computer Science (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DKPA201570518 | 2015-08-11 | ||
| DKPA201570518 | 2015-08-11 | ||
| AUPCT/EP2016/051467 | 2016-01-25 | ||
| PCT/EP2016/051467 WO2016120216A1 (en) | 2015-01-26 | 2016-01-25 | mAb-DRIVEN CHIMERIC ANTIGEN RECEPTOR SYSTEMS FOR SORTING/DEPLETING ENGINEERED IMMUNE CELLS |
| PCT/EP2016/067800 WO2017025323A1 (en) | 2015-08-11 | 2016-07-26 | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AU2016307050A1 true AU2016307050A1 (en) | 2018-02-15 |
Family
ID=53836344
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016307050A Abandoned AU2016307050A1 (en) | 2015-08-11 | 2016-07-26 | Cells for immunotherapy engineered for targeting CD38 antigen and for CD38 gene inactivation |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US10709775B2 (cg-RX-API-DMAC7.html) |
| EP (1) | EP3334442B1 (cg-RX-API-DMAC7.html) |
| JP (1) | JP2018522907A (cg-RX-API-DMAC7.html) |
| KR (1) | KR20180041152A (cg-RX-API-DMAC7.html) |
| CN (1) | CN108495641A (cg-RX-API-DMAC7.html) |
| AU (1) | AU2016307050A1 (cg-RX-API-DMAC7.html) |
| BR (1) | BR112018002600A2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2994746A1 (cg-RX-API-DMAC7.html) |
| IL (1) | IL257009A (cg-RX-API-DMAC7.html) |
| MX (1) | MX2018001776A (cg-RX-API-DMAC7.html) |
| RU (1) | RU2018107754A (cg-RX-API-DMAC7.html) |
| WO (1) | WO2017025323A1 (cg-RX-API-DMAC7.html) |
Families Citing this family (77)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013066438A2 (en) | 2011-07-22 | 2013-05-10 | President And Fellows Of Harvard College | Evaluation and improvement of nuclease cleavage specificity |
| US9163284B2 (en) | 2013-08-09 | 2015-10-20 | President And Fellows Of Harvard College | Methods for identifying a target site of a Cas9 nuclease |
| US9359599B2 (en) | 2013-08-22 | 2016-06-07 | President And Fellows Of Harvard College | Engineered transcription activator-like effector (TALE) domains and uses thereof |
| US9526784B2 (en) | 2013-09-06 | 2016-12-27 | President And Fellows Of Harvard College | Delivery system for functional nucleases |
| US9322037B2 (en) | 2013-09-06 | 2016-04-26 | President And Fellows Of Harvard College | Cas9-FokI fusion proteins and uses thereof |
| US9340799B2 (en) | 2013-09-06 | 2016-05-17 | President And Fellows Of Harvard College | MRNA-sensing switchable gRNAs |
| US20150166984A1 (en) | 2013-12-12 | 2015-06-18 | President And Fellows Of Harvard College | Methods for correcting alpha-antitrypsin point mutations |
| AU2015298571B2 (en) | 2014-07-30 | 2020-09-03 | President And Fellows Of Harvard College | Cas9 proteins including ligand-dependent inteins |
| CA2967222C (en) * | 2014-11-12 | 2023-10-31 | Rinat Neuroscience Corp. | Inhibitory chimeric antigen receptors |
| WO2017070632A2 (en) | 2015-10-23 | 2017-04-27 | President And Fellows Of Harvard College | Nucleobase editors and uses thereof |
| WO2017075537A1 (en) | 2015-10-30 | 2017-05-04 | Aleta Biotherapeutics Inc. | Compositions and methods for treatment of cancer |
| MA43134A (fr) | 2015-10-30 | 2018-09-05 | Aleta Biotherapeutics Inc | Compositions et méthodes de transduction tumorale |
| WO2018027078A1 (en) | 2016-08-03 | 2018-02-08 | President And Fellows Of Harard College | Adenosine nucleobase editors and uses thereof |
| AU2017308889B2 (en) | 2016-08-09 | 2023-11-09 | President And Fellows Of Harvard College | Programmable Cas9-recombinase fusion proteins and uses thereof |
| WO2018039438A1 (en) | 2016-08-24 | 2018-03-01 | President And Fellows Of Harvard College | Incorporation of unnatural amino acids into proteins using base editing |
| US10724043B2 (en) | 2016-10-06 | 2020-07-28 | Nantbio, Inc. | Multi-pulse transfection methods and cells |
| KR20240007715A (ko) | 2016-10-14 | 2024-01-16 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 핵염기 에디터의 aav 전달 |
| WO2018119359A1 (en) | 2016-12-23 | 2018-06-28 | President And Fellows Of Harvard College | Editing of ccr5 receptor gene to protect against hiv infection |
| KR20190123328A (ko) | 2017-03-09 | 2019-10-31 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 암 백신 |
| WO2018165504A1 (en) | 2017-03-09 | 2018-09-13 | President And Fellows Of Harvard College | Suppression of pain by gene editing |
| CN110914310A (zh) | 2017-03-10 | 2020-03-24 | 哈佛大学的校长及成员们 | 胞嘧啶至鸟嘌呤碱基编辑器 |
| IL306092A (en) | 2017-03-23 | 2023-11-01 | Harvard College | Nucleic base editors that include nucleic acid programmable DNA binding proteins |
| US11560566B2 (en) | 2017-05-12 | 2023-01-24 | President And Fellows Of Harvard College | Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation |
| CN109232742B (zh) * | 2017-07-11 | 2021-10-22 | 深圳市第二人民医院 | 一种嵌合抗原受体及其应用 |
| EP3654994B1 (en) * | 2017-07-18 | 2022-12-28 | CSL Behring Gene Therapy, Inc. | A modulatable switch for selection of donor modified cells |
| EP3658573A1 (en) | 2017-07-28 | 2020-06-03 | President and Fellows of Harvard College | Methods and compositions for evolving base editors using phage-assisted continuous evolution (pace) |
| EP3676376B1 (en) | 2017-08-30 | 2025-01-15 | President and Fellows of Harvard College | High efficiency base editors comprising gam |
| CA3082251A1 (en) | 2017-10-16 | 2019-04-25 | The Broad Institute, Inc. | Uses of adenosine base editors |
| KR20200076732A (ko) * | 2017-11-03 | 2020-06-29 | 소렌토 쎄라퓨틱스, 인코포레이티드 | Cd38-지시된 키메라 항원 수용체 작제물 |
| WO2019111249A1 (en) * | 2017-12-05 | 2019-06-13 | The Medical Research Infrastructure And Health Services Fund Of The Tel Aviv Medical Center | T-cells comprising anti-cd38 and anti-cd138 chimeric antigen receptors and uses thereof |
| US12139522B2 (en) | 2017-12-05 | 2024-11-12 | The Medical Research Infrastructure And Heal Serviced Fund Of The Tel Aviv Medecal Center | T-cells comprising two different chimeric antigen receptors and uses thereof |
| US12406749B2 (en) | 2017-12-15 | 2025-09-02 | The Broad Institute, Inc. | Systems and methods for predicting repair outcomes in genetic engineering |
| BR112020011017A2 (pt) | 2017-12-22 | 2020-11-17 | Fate Therapeutics, Inc. | células efetoras imunes intensificadas e uso das mesmas |
| AU2019216269B2 (en) * | 2018-01-30 | 2025-05-01 | Cellectis | Combination comprising allogeneic immune cells deficient for an antigen present on both T-cells and pathological cells and therapeutic antibody against said antigen |
| CN112041432A (zh) * | 2018-02-15 | 2020-12-04 | 纪念斯隆-凯特林癌症中心 | Foxp3靶向剂组合物以及用于过继细胞疗法的使用方法 |
| AU2019243315A1 (en) * | 2018-03-29 | 2020-09-24 | Fate Therapeutics, Inc. | Engineered immune effector cells and use thereof |
| WO2019226953A1 (en) | 2018-05-23 | 2019-11-28 | The Broad Institute, Inc. | Base editors and uses thereof |
| EP3820495A4 (en) | 2018-07-09 | 2022-07-20 | The Broad Institute Inc. | RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES |
| CN113395978A (zh) * | 2018-07-11 | 2021-09-14 | 动量制药公司 | 与靶向CTLA-4的工程化Fc-抗原结合结构域构建体有关的组合物和方法 |
| KR20210044218A (ko) * | 2018-07-11 | 2021-04-22 | 모멘타 파머슈티컬스 인코포레이티드 | CD38 표적화 조작된 Fc-항원 결합 도메인 작제물에 관련된 조성물 및 방법 |
| CA3110837A1 (en) | 2018-08-28 | 2020-03-05 | Vor Biopharma Inc. | Genetically engineered hematopoietic stem cells and uses thereof |
| CN109265551B (zh) * | 2018-09-25 | 2020-09-15 | 华东师范大学 | Cd38抗体、嵌合抗原受体和药物 |
| CN109293774B (zh) * | 2018-10-16 | 2021-05-28 | 南京医科大学 | 特异性结合cd19的全人源化抗体及应用 |
| WO2020092453A1 (en) | 2018-10-29 | 2020-05-07 | The Broad Institute, Inc. | Nucleobase editors comprising geocas9 and uses thereof |
| SG11202103832SA (en) * | 2018-11-07 | 2021-05-28 | Crispr Therapeutics Ag | Anti-cd33 immune cell cancer therapy |
| AU2019387377B2 (en) * | 2018-11-30 | 2026-07-09 | Lentigen Technology, Inc. | Compositions and methods for treating cancer with anti-CD38 immunotherapy |
| US12351837B2 (en) | 2019-01-23 | 2025-07-08 | The Broad Institute, Inc. | Supernegatively charged proteins and uses thereof |
| CN111676195A (zh) * | 2019-03-11 | 2020-09-18 | 北京卡替医疗技术有限公司 | 一种治疗t细胞肿瘤的ucar免疫细胞 |
| WO2020191241A1 (en) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Methods and compositions for editing nucleotide sequences |
| WO2020214842A1 (en) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Adenine base editors with reduced off-target effects |
| WO2020220027A1 (en) * | 2019-04-25 | 2020-10-29 | Purdue Research Foundation | Engineered natural killer cells redirected toward purinergic signaling, constructs thereof, and methods for using the same |
| AU2020299774A1 (en) | 2019-07-03 | 2022-01-20 | Peptidream Inc. | CD38-binding agents and uses thereof |
| WO2021009263A1 (en) * | 2019-07-16 | 2021-01-21 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Antibodies having specificity for cd38 and uses thereof |
| US12435330B2 (en) | 2019-10-10 | 2025-10-07 | The Broad Institute, Inc. | Methods and compositions for prime editing RNA |
| CN112876563B (zh) * | 2019-11-29 | 2022-08-16 | 康诺亚生物医药科技(成都)有限公司 | 药物组合物及其制备方法和应用 |
| JP7879804B2 (ja) * | 2019-12-06 | 2026-06-24 | フェイト セラピューティクス,インコーポレイテッド | 小化合物を使用するiPSC由来エフェクター免疫細胞の増強 |
| CN111909966B (zh) * | 2020-04-01 | 2021-09-21 | 苏州克睿基因生物科技有限公司 | 一种制备经修饰的免疫细胞的方法 |
| CN111484563B (zh) * | 2020-04-30 | 2020-11-10 | 徐州医科大学附属医院 | 一种抗cd38嵌合抗原受体及其应用 |
| CA3177481A1 (en) | 2020-05-08 | 2021-11-11 | David R. Liu | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence |
| WO2022056489A1 (en) * | 2020-09-14 | 2022-03-17 | Vor Biopharma, Inc. | Compositions and methods for cd38 modification |
| US11661459B2 (en) | 2020-12-03 | 2023-05-30 | Century Therapeutics, Inc. | Artificial cell death polypeptide for chimeric antigen receptor and uses thereof |
| IL303269A (en) | 2020-12-03 | 2023-07-01 | Century Therapeutics Inc | Genetically engineered cells and uses thereof |
| TW202241935A (zh) | 2020-12-18 | 2022-11-01 | 美商世紀治療股份有限公司 | 具有可調適受體專一性之嵌合抗原受體系統 |
| JP2024500189A (ja) | 2020-12-21 | 2024-01-04 | アロジーン セラピューティクス,インコーポレイテッド | プロテアーゼ活性化cd45ゲートcar |
| KR20250152662A (ko) | 2020-12-31 | 2025-10-23 | 사노피 | NKp46 및 CD123에 결합하는 다기능성 자연살해(NK) 세포 관여자 |
| MX2023008809A (es) | 2021-01-29 | 2023-08-04 | Allogene Therapeutics Inc | ATENUACIÓN O INACTIVACIÓN DE UNO O MÁS DE TAP2, NLRC5, ß2M, TRAC, RFX5, RFXAP Y RFXANK PARA MITIGAR EL RECONOCIMIENTO DE CÉLULAS T DE PRODUCTOS CELULARES ALOGÉNICOS. |
| WO2023081200A2 (en) * | 2021-11-03 | 2023-05-11 | Intellia Therapeutics, Inc. | Cd38 compositions and methods for immunotherapy |
| WO2023227790A1 (en) | 2022-05-27 | 2023-11-30 | Sanofi | Natural killer (nk) cell engagers binding to nkp46 and bcma variants with fc-engineering |
| US20240042030A1 (en) | 2022-07-29 | 2024-02-08 | Allogene Therapeutics, Inc. | Engineered cells with reduced gene expression to mitigate immune cell recognition |
| WO2024052318A1 (en) * | 2022-09-06 | 2024-03-14 | Institut National de la Santé et de la Recherche Médicale | Novel dual split car-t cells for the treatment of cd38-positive hematological malignancies |
| WO2024054678A2 (en) * | 2022-09-09 | 2024-03-14 | Regents Of The University Of Minnesota | Antibodies against fentanyl and analogs and methods of use thereof |
| CN121969385A (zh) | 2023-09-11 | 2026-05-01 | 丹娜-法伯癌症研究院 | 含有il-2变体以增强car t细胞的功能性的car-衔接子 |
| JP2025074700A (ja) * | 2023-10-30 | 2025-05-14 | 学校法人藤田学園 | 抗cd38-carを発現する細胞傷害性免疫担当細胞、その製造方法、および当該免疫担当細胞を含む医薬組成物 |
| KR20260105764A (ko) | 2023-10-30 | 2026-07-07 | 알로젠 테라퓨틱스 인코포레이티드 | 조작된 세포 |
| US20250262300A1 (en) * | 2024-02-16 | 2025-08-21 | Kite Pharma, Inc. | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy |
| TW202615096A (zh) * | 2024-07-19 | 2026-04-16 | 國立大學法人京都大學 | SARS-CoV-2感染症治療及/或預防用細胞及其製法 |
| CN120349403B (zh) * | 2025-04-23 | 2026-08-07 | 河南农业大学 | 一种抗猪流行性腹泻病毒n蛋白的单克隆抗体及其识别的抗原表位肽和应用 |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR901228A (fr) | 1943-01-16 | 1945-07-20 | Deutsche Edelstahlwerke Ag | Système d'aimant à entrefer annulaire |
| US4683195A (en) | 1986-01-30 | 1987-07-28 | Cetus Corporation | Process for amplifying, detecting, and/or-cloning nucleic acid sequences |
| GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
| US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
| US6905680B2 (en) | 1988-11-23 | 2005-06-14 | Genetics Institute, Inc. | Methods of treating HIV infected subjects |
| US5858358A (en) | 1992-04-07 | 1999-01-12 | The United States Of America As Represented By The Secretary Of The Navy | Methods for selectively stimulating proliferation of T cells |
| US6352694B1 (en) | 1994-06-03 | 2002-03-05 | Genetics Institute, Inc. | Methods for inducing a population of T cells to proliferate using agents which recognize TCR/CD3 and ligands which stimulate an accessory molecule on the surface of the T cells |
| US6534055B1 (en) | 1988-11-23 | 2003-03-18 | Genetics Institute, Inc. | Methods for selectively stimulating proliferation of T cells |
| US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
| GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
| DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
| EP0590058B1 (en) | 1991-06-14 | 2003-11-26 | Genentech, Inc. | HUMANIZED Heregulin ANTIBODy |
| ES2136092T3 (es) | 1991-09-23 | 1999-11-16 | Medical Res Council | Procedimientos para la produccion de anticuerpos humanizados. |
| WO1993011794A1 (en) | 1991-12-13 | 1993-06-24 | Xoma Corporation | Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof |
| GB9203459D0 (en) | 1992-02-19 | 1992-04-08 | Scotgen Ltd | Antibodies with germ-line variable regions |
| US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
| AU6704794A (en) | 1993-04-13 | 1994-11-08 | Sloan-Kettering Institute For Cancer Research | Protection of human bone marrow from high dose antifolate therapy using mutated human dihydrofolate reductase dna |
| US7175843B2 (en) | 1994-06-03 | 2007-02-13 | Genetics Institute, Llc | Methods for selectively stimulating proliferation of T cells |
| US6692964B1 (en) | 1995-05-04 | 2004-02-17 | The United States Of America As Represented By The Secretary Of The Navy | Methods for transfecting T cells |
| US7067318B2 (en) | 1995-06-07 | 2006-06-27 | The Regents Of The University Of Michigan | Methods for transfecting T cells |
| US6010613A (en) | 1995-12-08 | 2000-01-04 | Cyto Pulse Sciences, Inc. | Method of treating materials with pulsed electrical fields |
| US6642043B1 (en) | 1996-03-12 | 2003-11-04 | Sloan-Kettering Institute For Cancer Research | Double mutants of dihydrofolate reductase and methods of using same |
| US7572631B2 (en) | 2000-02-24 | 2009-08-11 | Invitrogen Corporation | Activation and expansion of T cells |
| US6867041B2 (en) | 2000-02-24 | 2005-03-15 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| US6797514B2 (en) | 2000-02-24 | 2004-09-28 | Xcyte Therapies, Inc. | Simultaneous stimulation and concentration of cells |
| HK1052372A1 (zh) | 2000-02-24 | 2003-09-11 | Xcyte Therapies, Inc. | 细胞的同步刺激和富集 |
| CN1826408B (zh) | 2003-03-14 | 2011-01-26 | 塞托·帕尔斯科技公司 | 大容量离体电穿孔法 |
| EP1660186B1 (en) | 2003-08-18 | 2013-12-25 | MedImmune, LLC | Humanization of antibodies |
| US20050042664A1 (en) | 2003-08-22 | 2005-02-24 | Medimmune, Inc. | Humanization of antibodies |
| ATE466933T1 (de) | 2005-03-15 | 2010-05-15 | Cellectis | I-crei-meganuklease-varianten mit modifizierter spezifität sowie verfahren zu ihrer herstellung und verwendung |
| EP2551282A3 (en) | 2005-03-23 | 2013-02-13 | Genmab A/S | Antibodies against CD38 for treatment of multiple myeloma |
| CA2805442C (en) | 2010-07-21 | 2020-05-12 | Sangamo Biosciences, Inc. | Methods and compositions for modification of an hla locus |
| US20140115726A1 (en) | 2011-04-05 | 2014-04-24 | Cellectis | New tale-protein scaffolds and uses thereof |
| EP3459560B1 (en) | 2011-04-08 | 2021-02-24 | The United States of America, as represented by The Secretary, Department of Health and Human Services | Anti-epidermal growth factor receptor variant iii chimeric antigen receptors and use of same for the treatment of cancer |
| WO2013074916A1 (en) | 2011-11-18 | 2013-05-23 | Board Of Regents, The University Of Texas System | Car+ t cells genetically modified to eliminate expression of t- cell receptor and/or hla |
| GB201206559D0 (en) | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
| SG10201806573TA (en) * | 2012-05-25 | 2018-09-27 | Cellectis | Methods for engineering allogeneic and immunosuppressive resistant t cell for immunotherapy |
| KR20150029714A (ko) | 2012-07-13 | 2015-03-18 | 더 트러스티스 오브 더 유니버시티 오브 펜실바니아 | 이중특이적 항체의 공-도입에 의한 car 세포의 활성 증강 |
| EP2877488B1 (en) | 2012-07-24 | 2021-02-24 | Cellectis | New modular base-specific nucleic acid binding domains from burkholderia rhizoxinica proteins |
| AU2013312838B2 (en) | 2012-09-04 | 2018-11-29 | Cellectis | Multi-chain chimeric antigen receptor and uses thereof |
| CA2912375C (en) * | 2013-05-13 | 2023-03-14 | Cellectis | Methods for engineering highly active t cell for immunotherapy |
| SI2997141T1 (sl) | 2013-05-13 | 2023-04-28 | Cellectis | CD19 specifični himerni antigenski receptor in njegova uporaba |
| JP6608807B2 (ja) | 2013-05-29 | 2019-11-20 | セレクティス | Rnaガイドcasヌクレアーゼ系を用いることによって免疫療法のためにt細胞を操作するための方法 |
| RU2752933C2 (ru) * | 2014-03-11 | 2021-08-11 | Селлектис | Способ создания т-клеток, пригодных для аллогенной трансплантации |
| TR201910814T4 (tr) * | 2014-03-19 | 2019-08-21 | Cellectis | Kanser immünoterapisi için cd123 spesifik kimerik antijen reseptörleri. |
| US20170296623A1 (en) * | 2014-12-17 | 2017-10-19 | Cellectis | INHIBITORY CHIMERIC ANTIGEN RECEPTOR (iCAR OR N-CAR) EXPRESSING NON-T CELL TRANSDUCTION DOMAIN |
| EP3250602A1 (en) * | 2015-01-26 | 2017-12-06 | Cellectis | T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to cd123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm |
-
2016
- 2016-07-26 CA CA2994746A patent/CA2994746A1/en not_active Abandoned
- 2016-07-26 BR BR112018002600-0A patent/BR112018002600A2/pt not_active IP Right Cessation
- 2016-07-26 WO PCT/EP2016/067800 patent/WO2017025323A1/en not_active Ceased
- 2016-07-26 CN CN201680046216.9A patent/CN108495641A/zh active Pending
- 2016-07-26 KR KR1020187006555A patent/KR20180041152A/ko not_active Withdrawn
- 2016-07-26 US US15/751,472 patent/US10709775B2/en active Active
- 2016-07-26 MX MX2018001776A patent/MX2018001776A/es unknown
- 2016-07-26 RU RU2018107754A patent/RU2018107754A/ru not_active Application Discontinuation
- 2016-07-26 JP JP2018506346A patent/JP2018522907A/ja not_active Withdrawn
- 2016-07-26 EP EP16751219.3A patent/EP3334442B1/en active Active
- 2016-07-26 AU AU2016307050A patent/AU2016307050A1/en not_active Abandoned
-
2018
- 2018-01-18 IL IL257009A patent/IL257009A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP3334442A1 (en) | 2018-06-20 |
| KR20180041152A (ko) | 2018-04-23 |
| MX2018001776A (es) | 2018-06-06 |
| WO2017025323A1 (en) | 2017-02-16 |
| RU2018107754A (ru) | 2019-09-12 |
| JP2018522907A (ja) | 2018-08-16 |
| IL257009A (en) | 2018-03-29 |
| CA2994746A1 (en) | 2017-02-16 |
| US20180236053A1 (en) | 2018-08-23 |
| RU2018107754A3 (cg-RX-API-DMAC7.html) | 2019-12-20 |
| US10709775B2 (en) | 2020-07-14 |
| BR112018002600A2 (pt) | 2018-10-23 |
| CN108495641A (zh) | 2018-09-04 |
| EP3334442B1 (en) | 2024-12-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP3334442B1 (en) | Cells for immunotherapy engineered for targeting cd38 antigen and for cd38 gene inactivation | |
| JP6673838B2 (ja) | 免疫細胞と病的細胞の両方に存在する抗原を標的とするように操作された、免疫療法のための細胞 | |
| EP3250606B1 (en) | Anti-cll1 specific single-chain chimeric antigen receptors (sccars) for cancer immunotherapy | |
| EP2997132B1 (en) | Methods for engineering allogeneic and highly active t cell for immunotherapy | |
| EP2893004B1 (en) | Multi-chain chimeric antigen receptor and uses thereof | |
| JP2023036657A (ja) | 修飾されたt細胞及びその使用方法 | |
| WO2019149743A1 (en) | Combination comprising allogeneic immune cells deficient for an antigen present on both t-cells and pathological cells and therapeutic antibody against said antigen | |
| CN119569895A (zh) | G蛋白偶合受体c类5族成员d(gprc5d)特异性嵌合抗原受体 | |
| JP2024505075A (ja) | 同種細胞産物のT細胞認識を軽減するための、TAP2、NLRC5、β2m、TRAC、RFX5、RFXAP及びRFXANKのうち1つ以上のノックダウン又はノックアウト | |
| CN114828862A (zh) | 使用融合蛋白进行tcr重编程的组合物和方法 | |
| JP2024526090A (ja) | 同種car t細胞の持続性を延長するための宿主cd70+アロ反応性細胞の選択的標的化 | |
| CN116724053A (zh) | 靶向sox2抗原的免疫治疗 | |
| US20240042030A1 (en) | Engineered cells with reduced gene expression to mitigate immune cell recognition | |
| US12577290B2 (en) | FasL expression and FasR gene knockout to protect therapeutic cells from allogeneic rejection and activation-induced cell death | |
| US20250262300A1 (en) | Systems, methods, and kits for generating and administering engineered t cells and cd38 targeting compounds as a combination therapy | |
| HK40119145A (en) | Engineered cells with reduced gene expression to mitigate immune cell recognition | |
| HK40103417A (en) | KNOCKDOWN OR KNOCKOUT OF ONE OR MORE OF TAP2, NLRC5, β2M, TRAC, RFX5, RFXAP AND RFXANK TO MITIGATE T CELL RECOGNITION OF ALLOGENEIC CELL PRODUCTS | |
| HK40107733A (en) | Selective targeting of host cd70+ alloreactive cells to prolong allogeneic car t cell persistence | |
| HK40097595A (en) | Immunotherapy targeting sox2 antigens | |
| HK1212728B (en) | Multi-chain chimeric antigen receptor and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK4 | Application lapsed section 142(2)(d) - no continuation fee paid for the application |